AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 22 min read$HSIC

Is Henry Schein (HSIC) Stock Undervalued Right Now?

Henry Schein (HSIC) is identified as a potential value stock with a Zacks Rank #2 (Buy) and a Value grade of A. Its P/E ratio of 13.27 is below its industry average of 17.58, and it shows attractive PEG, P/B, P/S, and P/CF ratios compared to industry averages. The analysis suggests HSIC may be undervalued.

Original reporting
finance.yahoo.com
Published Sep 2, 2026, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 2:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Is Henry Schein (HSIC) Stock Undervalued Right Now? — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HSICNeutralLow
01

Why it matters

The article does not introduce new data; it reiterates existing metrics, offering limited actionable insight.

02

Market read

Low relevance; serves more as educational content than a news event.

03

What to watch

Potential risks like margin pressure from supply‑chain costs or competitive pressure from online dental suppliers are not discussed.

Relevance 4/10Novelty 2/10Timing: none

Background

The piece is a value‑investment style analysis from a financial website, referencing Zacks Rank and various valuation multiples.

Company-level read

Ticker impact

$HSICNeutralHigh confidence
Context

The article provides a valuation‑focused commentary on Henry Schein (HSIC) without presenting any new corporate event or data.

Expected impact

Limited impact; price likely unchanged absent fresh catalyst.

Evidence & confidence

All figures quoted (P/E, PEG, P/B, etc.) are publicly known and not newly disclosed.

Market effects

Sector

None; the commentary does not alter sector outlook for healthcare distribution.

Regional

None; no regional market effect identified.

Global

Minimal; article is a niche valuation piece.

Counterpoint

What could challenge this read

If investors believe HSIC is undervalued, they may still wait for a catalyst such as earnings beat or acquisition rumor before acting.

Key entities

  • company
    Henry Schein, Inc.

    Healthcare products distributor, ticker HSIC.

Read at source← All news

Related articles

SEP 15
$HSICMed

HSIC: Growth acceleration, operational rigor, and disciplined capital allocation drive strong performance

Henry Schein, Inc. [HSIC] outlined plans to accelerate growth, simplify operations, and improve operating income by $200 million, targeting double-digit EPS growth. The company highlighted strong performance in dental and medical segments, focusing on consumables, private label, and technology. Leadership emphasized disciplined M&A and share buybacks for capital allocation.

tradingview.com1 min
AUG 19
$HSICMed

Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?

Henry Schein, Inc. (HSIC) reported broad-based growth in Q2, with sales increases across distribution, specialty products, and technology. Management raised its 2026 sales and earnings guidance. HSIC trades at a discount to market benchmarks but faces risks from leverage and execution challenges. The company aims for $200M in operating income improvement by 2026, with savings initiatives underway.

tradingview.com3 min
AUG 11
$HSICMedAI 8/10

Henry Schein (HSIC) Q2 2026 Earnings Call Transcript

Henry Schein (HSIC) reported Q2 2026 net sales of $3.5 billion, up 6.7%, and non-GAAP diluted EPS of $1.27. GAAP diluted EPS was $0.82. The company raised 2026 guidance, including non-GAAP EPS to $5.29 to $5.39 and sales growth to 4.5% to 5.5%, and approved $200 million in share repurchases.

fool.com6 min
AUG 7
$HSICMed

Henry Schein Recasts Its Future Around AI, Simpler Leadership and Faster Execution

Henry Schein Inc. outlined a transformation focused on AI, simpler leadership, and faster execution in its first earnings report under CEO Fred Lowery. The company reported Q2 net sales of $3.46B (+6.7%) and net income of $94M (+9.3%), raised its 2026 sales outlook to 4.5% to 5.5%, and announced a leadership reorganization integrating supply chain and distribution. It targets $200M+ operating improvements.

distributionstrategy.com7 min
AUG 6
$HSICMedAI 8/10

Henry Schein, Inc. Q2 2026 Earnings Call Summary

Henry Schein reported Q2 2026 progress including faster internal local-currency sales growth, driven by dental merchandise market-share gains and higher technology platform share. The company raised full-year 2026 sales growth guidance to 4.5% to 5.5% and expects $125 million operating income improvement run rate by end-2026. Restructuring expenses were $29 million.

yahoo.com6 min